Palvella Therapeutics, Inc. Unrealized Gain (Loss) on Derivatives
Palvella Therapeutics, Inc. (PVLA) reported Unrealized Gain (Loss) on Derivatives of -$114.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2026-08-04
- Palvella Therapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2026-06-30 was -$114.00K.
- Palvella Therapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2026-03-31 was -$116.00K.
- Palvella Therapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2025-12-31 was -$119.00K.
- Palvella Therapeutics, Inc. unrealized gain (loss) on derivatives for the quarter ending 2025-09-30 was -$82.00K.
- Palvella Therapeutics, Inc. unrealized gain (loss) on derivatives for fiscal 2025 was -$394.00K.
- Palvella Therapeutics, Inc. unrealized gain (loss) on derivatives for fiscal 2024 was -$633.00K, a 230.52% decline from fiscal 2023.
- Palvella Therapeutics, Inc. unrealized gain (loss) on derivatives for fiscal 2023 was $485.00K.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$114.00K 10-Q · filed 2026-08-04 | -$230.00K 10-Q · filed 2026-08-04 | -$349.00K derived: sum of 3 quarters · filed 2026-08-04 | -$431.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$116.00K 10-Q · filed 2026-05-07 | -$235.00K derived: sum of 2 quarters · filed 2026-05-07 | -$317.00K derived: sum of 3 quarters · filed 2026-05-07 | -$435.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$201.00K derived: sum of 2 quarters · filed 2026-03-31 | -$319.00K derived: sum of 3 quarters · filed 2026-08-04 | -$394.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$82.00K 10-Q · filed 2025-11-12 | -$200.00K derived: sum of 2 quarters · filed 2026-08-04 | -$275.00K 10-Q · filed 2025-11-12 | -$504.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$118.00K 10-Q · filed 2026-08-04 | -$193.00K 10-Q · filed 2026-08-04 | -$422.00K derived: sum of 3 quarters · filed 2026-08-04 | -$497.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$75.00K 10-Q · filed 2026-05-07 | -$304.00K derived: sum of 2 quarters · filed 2026-05-07 | -$379.00K derived: sum of 3 quarters · filed 2026-05-07 | -$650.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$229.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$304.00K derived: sum of 2 quarters · filed 2026-03-31 | -$575.00K derived: sum of 3 quarters · filed 2026-03-31 | -$633.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$75.00K 10-Q · filed 2025-11-12 | -$346.00K derived: sum of 2 quarters · filed 2025-11-12 | -$404.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$271.00K 10-Q · filed 2025-08-14 | -$329.00K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$58.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $485.00K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |